Persistence of IgM SARS-COV-2 in patients who completed quarantine for COVID-19, in Arequipa, Peru
DOI:
https://doi.org/10.31052/1853.1180.v29.n1.32051Keywords:
Coronavirus Infections, Serology, Immunoglobulin M, False Positive Reactions, Rheumatoid FactorAbstract
Objective: To analyze clinical characteristics of convalescent patients for COVID-19 who show persistence of IgM.
Materials and methods: Analytical study; 614 patients were evaluated from day 21 to 175 after onset of symptoms. There were 19 cases with positive IgM (3.1%). A control group was used to compare clinical variables, grouping them into categories and applying chi-squared test or Fisher's exact test (p <0.05).
Results: Cases of positive IgM were recorded from the end of quarantine (day 21), reaching the highest number during the 44-65-day interval (42.1%). An association was found between the presence of positive IgM and autoimmune diseases (p = 0.02).
Conclusions: There is persistence of SARS-CoV-2 IgM positivity up to 175 days after the onset of symptoms, mainly associated with cross-reactivity with autoimmune diseases. This provides useful information to clarify causes and help in medical management.
Keywords: coronavirus infections; serology; immunoglobulin M, false positive reactions; autoimmune diseases.
Downloads
References
Zhang Z, Xiao K, Zhang X, Roy A, Shen Y. Emergence of SARS-like coronavirus in China: an update. J Infect 2020, 80 (5): e28-e29. doi: 10.1016/j.jinf.2020.03.010
Mercado M, Malagón-Rojas J, Delgado G, Rubio V, Muñoz L, Parra E, et al. Evaluation of nine serological rapid tests for the detection of SARS-CoV-2. Rev Panam Salud Publica. 2020; 44: e149. doi: 10.26633/RPSP.2020.149
Loeffelholz M, Yi-Wei Tang Y. Laboratory diagnosis of emerging human coronavirus infections – the state of the art, Emerging Microbes & Infections, 2020. 9: (1): 747-756. doi: 10.1080/22221751.2020.1745095
Cañete P, Vinuesa C, COVID-19 makes B cells forget, but T cells remember, Cell, 2020, S0092-8674 (20): 31154-5. doi: 10.1016/j.cell.2020.09.013.
Barnes C, West A, Huey-Tubman K, Hoffmann M, Sharaf N, Hoffman P, et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies, Cell, 2020, S0092-8674 (20): 30757-1. doi: 10.1016/j.cell.2020.06.025.
Isho B, Abe K, Zuo M, Jamal A, Rathod B, Wang J, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci. Immunol. 2020. 5 (52): eabe5511. doi: 10.1126/sciimmunol.abe5511
Sheridan C. Fast, portable tests come online to curb coronavirus pandemic. Nat Biotechnol. 2020; 38 (5): 515-518. doi: 10.1038/d41587-020-00010-2.
Wang Q, Du Q, Guo B, Mu D, Lu X, Ma Q, et al. A method to prevent SARS-CoV-2 IgM false positives in gold immunochromatography and enzymelinked immunosorbent assays. J Clin Microbiol. 2020; 58: e00375-20. doi: 10.1128/JCM.00375-20
Hernández-Pérez J. Martín-González E, Pino M, Strengths and weakness of diagnostic tests of SARS CoV-2infection. Med Clin (Barc). 2020; 155 (10): 463–469. doi: 10.1016/j.medcli.2020.05.019
Stadlbauer D, Amanat F, Chromikova V, Teo C, McMahon M, Simon V. et al. SARS-CoV-2 Seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr Protoc Microbiol, 2020; 57 (1): e100. doi: 10.1002/cpmc.100
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Antibody responses to SARS-CoV-2 in patients of novel coronavirus. Clinical Infectious Diseases, 71 (16): 2027–2034. doi: 10.1093/cid/ciaa344
Lozada I, Nuñez C. COVID-19: respuesta inmune y perspectivas terapéuticas. Rev. perú. med. exp. salud pública. 2020, 37 (2): 312-319. doi: 10.17843/rpmesp.2020.372.5490
Mikuls T, Johnson S, Fraenkel L, Arasaratnam R, Baden L, Bermas B, et al. American College of Rheumatology guidance for the management of adult patients with rheumatic disease during the COVID-19 pandemic, Arthritis Rheumatol. 2020; 72 (8): 1241-1251. doi: 10.1002/art.41301
Renzo Reynaldo GM. Current Clinical-Epidemiological Profile of Patients with COVID-19 in Reference Hospital of Perú. American J Epidemiol Public Health. 2020; 4 (3): 081-085. doi: 10.37871/ajeph.id35
Nath H, Mallick A, Roy S, Sukla S, Basu K, De A, et al. Dengue antibodies can cross-react with SARS-CoV-2 and vice versa-Antibody detection kits can give false-positive results for both viruses in regions where both COVID-19 and Dengue co-exist. medRxiv 2020 (Preprint): 20145797. doi: 10.1101/2020.07.03.20145797
Vinyé M, Bausà R, Corominasa H. Cross-reactions between rheumatoid factor and IgM SARS-CoV-2. Med Clin (Barc). 2020; 155 (9): 414–420. doi: 10.1016/j.medcli.2020.07.008
Carfì A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. JAMA 2020. 324 (6): 603-605. doi:10.1001/jama.2020.12603
Jiang M, Li Y, Han M, Wang Z, Zhang Y. Recurrent PCR positivity after hospital discharge of people with coronavirus disease 2019 (COVID-19). Journal of Infection, 2020. 81: 162–164. doi: 10.1016/j.jinf.2020.03.024
Stavem K, Ghanima W, Olsen K, Gilboe H, Einvik G. Persistent symptoms 1.5–6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax, 2020; 0: 1–3 (Epub ahead of print). doi: 10.1136/thoraxjnl-2020-216377
Mo H, Zeng G, Ren X, Li H, Ke Ch, Tan Y. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology, 2006, 11 (1): 49–53. doi: 10.1111/j.1440-1843.2006.00783.x
To K, Tsang O, Leung W, Tam A, Wu T, Lung D, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020; 20 (5): 565-574. doi:10.1016/S1473-3099(20)30196-1
Patel R, Babady E, Theel E, Pinsky B, St. George K, Tara C. Smith T, Bertuzzi S. Report from the American Society for Microbiology COVID-19 international summit, 23 March 2020: value of diagnostic testing for SARS-CoV-2/COVID-19. mBio 2020; 11 (2): e00722-20. Doi: 10.1128/mBio.00722-20.
Lou B, Li T, Zheng SF, Su Y, Li Z, Liu W, et al. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. Eur Respir J. 2020: 2000763 [Epub ahead of print]. doi: 10.1183/13993003.00763-2020
Gussin H, Russo K, Teodorescu M. Effect of circulating immune complexes on the binding of rheumatoid factor to histones. Ann Rheum Dis 2000; 59 (5): 351–358. doi.org/10.1136/ard.59.5.351
Rojko J, Evans M, Price S, Han B, Waine G, DeWitte M, et al. Formation, Clearance, Deposition, Pathogenicity, and Identification of Biopharmaceutical-related Immune Complexes: Review and Case Studies. Toxicologic Pathology, 42: 725-764, 2014. doi: 10.1177/0192623314526475
Hutt M, Färber-Schwarz A, Unverdorben F, Richter F, Kontermann R. Plasma Half-life Extension of Small Recombinant Antibodies by Fusion to Immunoglobulin-binding Domains. The Journal of Biological Chemistry, 2011, 287 (7): 4462-4469. doi: 10.1074/jbc.m111.311522
Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in Immune-Mediated Inflammatory Diseases. Case Series from New York. Engl J Med, 2020; 383: 85-88. doi: 10.1056/NEJMc2009567
Zhang L, Shen F, Chen F, Lin Z. Origin and evolution of the 2019 novel coronavirus. Clin Infect Dis, 2020. 71 (15): 882-883. doi: 10.1093/cid/ciaa112.
Moderbacher C, Ramirez S, Dan J, Grifoni A, Hastie K, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell, 2020, S0092-8674 (20): 31235-6. doi: 10.1016/j.cell.2020.09.038.
Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of nucleocapsid and spike protein-based ELISAs for detecting antibodies against SARS-CoV-2. J Clin Microbiol. 2020, 58 (6): e00461-20. doi: 10.1128/jcm.00461-20.
Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, 2020. 584: 115–119. doi: 10.1038/s41586-020-2380-z
Bosch A, Biesbroek G, Trzcinski K, Sanders E, Bogaert D. Viral and Bacterial Interactions in the Upper Respiratory Tract. PLoS Pathogens, 2013. 9 (1): e1003057. doi: 10.1371/journal.ppat.1003057
Moscola J, Sembajwe G, Jarrett M, Farber B, Chang T, McGinn T, et al. Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the NewYork City Area. 2020. JAMA. 2020; 324 (9): 893-895. doi:10.1001/jama.2020.14765
Carabaña Morales J. Datos de encuesta para estimar la prevalencia de COVID-19. Un estudio piloto en Madrid capital. Rev Esp Salud Pública. 2020; 94: 17 de noviembre e202011159
Muñoz L, Pífano M, Bolzán A, Varela T, Comes Y, Specogna M, et al. Vigilancia y Seroprevalencia: Evaluación de anticuerpos IgG para SARS-Cov2 mediante ELISA en el barrio popular Villa Azul, Quilmes, Provincia de Buenos Aires, Argentina. Scielo (preprints). doi: 10.1590/SciELOPreprints.1147
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Escuela de Salud Pública y Ambiente. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License which allows the work to be copied, distributed, exhibited and interpreted as long as it is not done for commercial purposes.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication process. (See The Effect of Open Access). (See The Effect of Open Access).
How to Cite
